The effects of po-TACE treatment on HCC prognosis stratified by ADAs
ADA
Po-TACE treatment
OS
RFS
DR (95% CI)a
Ptrend
TRR (95% CI)a
Ptrend
Low
Yes vs. no
0.84 (0.58–1.20)
0.33
0.84 (0.58–1.23)
0.37
High
Yes vs. no
0.36 (0.24–0.53)
2.67 × 10–7
0.40 (0.28–0.59)
2.00 × 10–6
a Adjusted by age, sex, race, HBV and HCV status, smoking and drinking status, AFP, liver cirrhosis, and tumor grade. Ptrend: P value is calculated by trend test in the models
Declarations
Acknowledgement
We thank Dr. Qiu-Xiang Liang, Dr. Yun Yi, Yun Xia, Yong-Zhi Huang, and Dr. Yuan-Feng Zhou for sample collection and management, Dr. Hua Huang for molecular biochemical technique.
Author contributions
LYH and QQL: Methodology, Formal analysis, Data curation, Writing—review & editing. QYS: Investigation, Resource, Writing—review & editing. XYZ: Investigation, Formal analysis, Writing—review & editing. XDL: Conceptualization, Funding acquisition, Supervision, Project administration, Writing—original draft, Writing—review & editing. All authors read and approved the submitted version.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Ethical approval
The collection of removed tumor samples and clinicopathological information are approved by the Ethics Committee of Youjiang Medical University for Nationalities, China (No. AYJM20150118) and comply with the Declaration of Helsinki.
Consent to participate
Informed consent to participate in the study was obtained from all participants.
Consent to publication
Not applicable.
Availability of data and materials
Not applicable.
Funding
This study was supported in part by Guangxi Training Program for Medical High-level Academic Leaders [Guiweikejiaofa (2020)-15], Bose Talent Highland [2020-3-2], Building Projects from the Key Laboratory of Molecular Pathology (Hepatobiliary Diseases) of Guangxi [Guiweikejiaofa (2020)-17] and the Key Laboratory of Tumor Molecular Pathology of Guangxi Colleges & Universities [Guijiaokeyan (2022)-10], and Clinical Key Specialty Building Project (For Pathology) of Guangxi [Guiweiyifa (2022)-21]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Deng Y, Wu XM, Huang XY, Long XD. X-ray repair cross complementing 4 (XRCC4) genetic single nucleotide polymorphisms and the liver toxicity of AFB1 in hepatocellular carcinoma. In: Long XD, editor. Aflatoxin B1 occurrence, detection and toxicological effects. Rijeka: IntechOpen; 2019. pp. 1–21.
Li C, Liu X, Wu J, Ji X, Xu Q. Research progress in toxicological effects and mechanism of aflatoxin B1 toxin.PeerJ. 2022;10:e13850. [DOI] [PubMed] [PMC]
Cao W, Yu P, Yang K, Cao D. Aflatoxin B1: metabolism, toxicology, and its involvement in oxidative stress and cancer development.Toxicol Mech Methods. 2022;32:395–419. [DOI] [PubMed]
Long XD, Deng Y, Huang XY, Yao JG, Su QY, Wu XM, et al. Molecular mechanisms of hepatocellular carcinoma related to aflatoxins: an update. In: Rodrigo L, editor. Liver research and clinical management. Rijeka: IntechOpen; 2017. pp. 113–36.
Moon J, Kitty I, Renata K, Qin S, Zhao F, Kim W. DNA damage and its role in cancer therapeutics.Int J Mol Sci. 2023;24:4741. [DOI] [PubMed] [PMC]
Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Targeting DNA damage response pathways in cancer.Nat Rev Cancer. 2023;23:78–94. [DOI] [PubMed]
Shetake NG, Ali M, Kumar A, Bellare J, Pandey BN. Theranostic magnetic nanoparticles enhance DNA damage and mitigate doxorubicin-induced cardio-toxicity for effective multi-modal tumor therapy.Biomater Adv. 2022;142:213147. [DOI] [PubMed]
Matuz-Mares D, Vázquez-Meza H, Vilchis-Landeros MM. NOX as a therapeutic target in liver disease.Antioxidants (Basel). 2022;11:2038. [DOI] [PubMed] [PMC]
Jurkovicova D, Neophytou CM, Gašparović AČ, Gonçalves AC. DNA damage response in cancer therapy and resistance: challenges and opportunities.Int J Mol Sci. 2022;23:14672. [DOI] [PubMed] [PMC]
Yang S, Wang XQ. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.BMC Cancer. 2017;17:344. [DOI] [PubMed] [PMC]
Nagahashi M, Matsuda Y, Moro K, Tsuchida J, Soma D, Hirose Y, et al. DNA damage response and sphingolipid signaling in liver diseases.Surg Today. 2016;46:995–1005. [DOI] [PubMed] [PMC]
Zhang TQ, Su QQ, Huang XY, Yao JG, Wang C, Xia Q, et al. Micro RNA-4651 serves as a potential biomarker for prognosis when selecting hepatocellular carcinoma patients for postoperative adjuvant transarterial chemoembolization therapy.Hepatol Commun. 2018;2:1259–73. [PubMed] [PMC]
Huang XY, Yao JG, Huang BC, Ma Y, Xia Q, Long XD. Polymorphisms of a disintegrin and metalloproteinase with thrombospondin motifs 5 and aflatoxin B1-related hepatocellular carcinoma.Cancer Epidemiol Biomarkers Prev. 2016;25:334–43. [DOI] [PubMed]
Li J, Xu Y, Long XD, Wang W, Jiao HK, Mei Z, et al. Cbx4 governs HIF-1α to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity.Cancer Cell. 2014;25:118–31.Erratum in: Cancer Cell. 2014;25:547–8. [DOI] [PubMed]
Long XD, Yao JG, Zeng Z, Ma Y, Huang XY, Wei ZH, et al. Polymorphisms in the coding region of X-ray repair complementing group 4 and aflatoxin B1-related hepatocellular carcinoma.Hepatology. 2013;58:171–81. [DOI] [PubMed]
Liu YX, Long XD, Xi ZF, Ma Y, Huang XY, Yao JG, et al. MicroRNA-24 modulates aflatoxin B1-related hepatocellular carcinoma prognosis and tumorigenesis.Biomed Res Int. 2014;2014:482926. [DOI] [PubMed] [PMC]
Curtin NJ. Targeting the DNA damage response for cancer therapy.Soc Trans. 2023;51:207–21. [DOI] [PubMed] [PMC]
Raimundo L, Calheiros J, Saraiva L. Exploiting DNA damage repair in precision cancer therapy: BRCA1 as a prime therapeutic target.Cancers (Basel). 2021;13:3438. [DOI] [PubMed] [PMC]
Jiao HK, Xu Y, Li J, Wang W, Mei Z, Long XD, et al. Prognostic significance of Cbx4 expression and its beneficial effect for transarterial chemoembolization in hepatocellular carcinoma.Cell Death Dis. 2015;6:e1689. [DOI] [PubMed] [PMC]
Zhong BY, Jin ZC, Chen JJ, Zhu HD, Zhu XL. Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma.J Clin Transl Hepatol. 2023;11:480–9. [DOI] [PubMed] [PMC]
Kotsifa E, Vergadis C, Vailas M, Machairas N, Kykalos S, Damaskos C, et al. Transarterial chemoembolization for hepatocellular carcinoma: why, when, how?J Pers Med. 2022;12:436. [DOI] [PubMed] [PMC]
Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection.J Hepatol. 2015;62:1187–95. [DOI] [PubMed]
Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.Cardiovasc Intervent Radiol. 2010;33:41–52. [DOI] [PubMed] [PMC]
Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma.Br J Cancer. 2014;111:255–64. [DOI] [PubMed] [PMC]
Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, et al. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).Liver Cancer. 2020;9:682–720. [DOI] [PubMed] [PMC]
Yang B, Cong W, Zhou X, Chen X, Yang J, Fan J, et al. Diagnosis and treatment of primary liver cancer: a standardized expert consensus.Chin Clin Oncol. 2009;14:259–69.
Long XD, Ma Y, Wei YP, Deng ZL. The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China.Hepatol Res. 2006;36:48–55. [DOI] [PubMed]
Long XD. Aflatoxin B1 occurrence, detection and toxicological effects. Rijeka: IntechOpen; 2020.
da Costa AABA, Chowdhury D, Shapiro GI, D’Andrea AD, Konstantinopoulos PA. Targeting replication stress in cancer therapy.Nat Rev Drug Discov. 2023;22:38–58. [DOI] [PubMed]
Long XD, Ma Y, Qu DY, Liu YG, Huang ZQ, Huang YZ, et al. The polymorphism of XRCC3 codon 241 and AFB1-related hepatocellular carcinoma in Guangxi population, China.Ann Epidemiol. 2008;18:572–8. [DOI] [PubMed]
Long XD, Ma Y, Zhou YF, Yao JG, Ban FZ, Huang YZ, et al. XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk.BMC Cancer. 2009;9:400. [DOI] [PubMed] [PMC]
Long XD, Zhao D, Wang C, Huang XY, Yao JG, Ma Y, et al. Genetic polymorphisms in DNA repair genes XRCC4 and XRCC5 and aflatoxin B1-related hepatocellular carcinoma.Epidemiology. 2013;24:671–81. [DOI] [PubMed]
Long XD, Ma Y, Zhou YF, Ma AM, Fu GH. Polymorphism in xeroderma pigmentosum complementation group C codon 939 and aflatoxin B1-related hepatocellular carcinoma in the Guangxi population.Hepatology. 2010;52:1301–9. [DOI] [PubMed]
Xia Q, Huang XY, Xue F, Zhang JJ, Zhai B, Kong D, et al. Genetic polymorphisms of DNA repair genes and DNA repair capacity related to aflatoxin B1 (AFB1)-induced DNA damages. In: Chen C, editor. New research directions in DNA repair. Rijeka: IntechOpen; 2013. pp. 375–413.
Long XD, Long ZX, Huang XY, Yao JG, Xia Q, Deng Y. Hepatocarcinoma angiogenesis and DNA damage repair response: an update. In: Mognato M, editor. DNA repair. Rijeka: IntechOpen; 2018. pp. 51–67.
Su QY, Lu J, Huang XY, Yao JG, Wu XM, Huang BC, et al. CBX4 expression and AFB1-related liver cancer prognosis. In: Lemamy GJ, editor. Cancer prognosis. Rijeka: IntechOpen; 2018. pp. 51–67.
Zhu XY, Huang MJ, Su QY, Wang XZ, Wang J, Long QQ, et al. The predictive potential of genetic single nucleotide polymorphisms in CBX4 for hepatocellular carcinoma survival.Front Biosci (Landmark Ed). 2021;26:1191–203. [DOI] [PubMed]
Zhang S, Zhong BY, Zhang L, Wang WS, Ni CF. Transarterial chemoembolization failure/refractoriness: a scientific concept or pseudo-proposition.World J Gastrointest Surg. 2022;14:528–37. [DOI] [PubMed] [PMC]
